Insight Molecular Diagnostics Inc. (IMDX)
(Delayed Data from NSDQ)
$2.56 USD
+0.04 (1.59%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $2.55 -0.01 (-0.39%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
IMDX 2.56 +0.04(1.59%)
Will IMDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMDX
3 Medical Info Systems Stocks to Buy Amid AI Boom and Tariff Risk
IMDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for IMDX
IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft ...
iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant ...
12 Health Care Stocks Moving In Friday's After-Market Session
Insight Molecular Diagnostics (IMDX) Gets a Buy from Lake Street
Insight Molecular Diagnostics (IMDX) Makes Strides in Transplant Rejection Testing | IMDX Stock News